Instructions For Use Figure A (Image 01)
Wixela Inhub Powder
Product Images NDC 0378-9322
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Wixela Inhub (NDC 0378-9322). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fluticasone Propionate Structural Formula (Image 02)
Salmeterol Zinofoate Structural Formula (Image 03)
Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 04)
This appears to be a table of data related to the use of Fluicasone propionate and Salmeterol as a treatment for some medical condition. There are some numerical values mentioned such as the quantity of Fluicasone propionate and Salmeterol to be taken twice daily. The table also seems to indicate the progress of the treatment over several weeks. However, without additional context or better results, it is difficult to provide further details.*
Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 05)
The text describes a table or graph showing the percentage change in FEV on the first treatment day of four different medications, including Fluticasone propionate and Salmeterol. The number of participants for each medication is also mentioned. A baseline measurement is also shown.*
Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Image 06)
Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Image 07)
This is a description of a study that evaluates the efficacy of Fluticasone propionate and Salmeterol inhalation powder in patients with a baseline forced expiratory volume (FEV) of 1207 mL. The patients were divided into two groups, one group received 250mog/50mog of Fluticasone propionate and Salmeterol twice daily, and the other group received a placebo. The study reports the percentage change in FEV at various endpoints.*
Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Image 08)
This appears to be a medical study's results regarding the impact of using Fluticasone propionate and Salmeterol inhalation to improve FEV (forced expiratory volume) in individuals. The study involved using different doses of Fluticasone propionate and a placebo. The results show the changes in FEV after different treatments.*
Instructions For Use Figure B (Image 09)
Instructions For Use Figure C (Image 10)
Instructions For Use Figure D (Image 11)
Instructions For Use Figure F (Image 12)
Instructions For Use Figure G (Image 13)
Instructions For Use Dose Counter Figure 1 (Image 14)
Instructions For Use Dose Counter Figure 2 (Image 15)
Instructions For Use Dose Counter Figure 3 (Image 16)
Instructions For Use Figure E (Image 17)
Instructions For Use Figure H (Image 18)
Wixela 100/50 Carton Label Step 3a (Image 19)
Wixela 100/50 Carton Label Step 2 (Image 20)
Wixela 100/50 Carton Label Step 3b (Image 21)
Wixela 100/50 Carton Label Step 1 (Image 22)
Wixela 100/50 Carton Label Step 4 (Image 23)
Wixela is a medication used for oral inhalation only. It contains fluticasone propionate and salmeterol inhalation powder. The dosage should be taken as directed by your doctor. The medication comes in a powder form, which needs to be inhaled. The inhaler needs to be stored at a controlled temperature between 20°C and 25°C. The inhaler needs to be discarded after use. After inhalation, you should rinse your mouth with water. If you face any issues or have any doubts, consult your doctor.*
Wixela 250/50 Carton Label Step 3a (Image 24)
Wixela Inhalation Powder 100/50 Carton Label (Image 25)
Wixela 250/50 Carton Label Step 3b (Image 26)
Wixela 250/50 Carton Label Step 1 (Image 27)
Wixela 250/50 Carton Label Step 2 (Image 28)
Wixela Inhalation Powder 250/50 Carton Label (Image 29)
Wixela 250/50 Carton Label Step 4 (Image 30)
Wixela 500/50 Carton Label Step 3a (Image 31)
Wixela 500/50 Carton Label Step 1 (Image 32)
Wixela 500/50 Carton Label Step 2 (Image 33)
Wixela 500/50 Carton Label Step 3b (Image 34)
Wixela 500/50 Carton Label Step 4 (Image 35)
Wixela is a prescribed inhalation powder, for oral use only. It contains fluticasone propionate and salmeterol, which are bronchodilators that help to make breathing easier by relaxing muscles in the airways. Each container holds 60 doses of inhalation powder. Before using it, read the enclosed patient information. The inhaler is easy to use, and each dose contains 500 mcg of fluticasone proponats and 72.5 g of salmeterol base. After use, rinse your mouth with water. Store the product in a cool, dry place, between 68-77 degrees Fahrenheit.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
